摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

8-氟-1,2,3,4-四氢异喹啉 | 123594-01-4

中文名称
8-氟-1,2,3,4-四氢异喹啉
中文别名
——
英文名称
8-fluoro-1,2,3,4-tetrahydroisoquinoline
英文别名
——
8-氟-1,2,3,4-四氢异喹啉化学式
CAS
123594-01-4
化学式
C9H10FN
mdl
——
分子量
151.184
InChiKey
BQEDHMMZSRJZSN-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    234.9±40.0 °C(Predicted)
  • 密度:
    1.107

计算性质

  • 辛醇/水分配系数(LogP):
    1.4
  • 重原子数:
    11
  • 可旋转键数:
    0
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.33
  • 拓扑面积:
    12
  • 氢给体数:
    1
  • 氢受体数:
    2

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    8-氟-1,2,3,4-四氢异喹啉 、 TERT-BUTYL TRANS-4-(2-OXOETHYL)CYCLOHEXYLCARBAMATE 在 三乙酰氧基硼氢化钠 作用下, 以 二氯甲烷 为溶剂, 生成
    参考文献:
    名称:
    D2 Dopamine Receptor G Protein-Biased Partial Agonists Based on Cariprazine
    摘要:
    Functionally selective G protein-coupled receptor ligands are valuable tools for deciphering the roles of downstream signaling pathways that potentially contribute to therapeutic effects versus side effects. Recently, we discovered both G(i/o)-biased and beta-arrestin2-biased D-2 receptor agonists based on the Food and Drug Administration (FDA)-approved drug aripiprazole. In this work, based on another FDA-approved drug, cariprazine, we conducted a structure-functional selectivity relationship study and discovered compound 38 (MS1768) as a potent partial agonist that selectively activates the G(i/o) pathway over beta-arrestin2. Unlike the dual D2R/D3R partial agonist cariprazine, compound 38 showed selective agonist activity for D2R over D3R. In fact, compound 38 exhibited potent antagonism of dopamine-stimulated beta-arrestin2 recruitment. In our docking studies, compound 38 directly interacts with S193(5.42) on TM5 but has no interactions with extracellular loop 2, which appears to be in contrast to the binding poses of D2R beta-arrestin2-biased ligands. In in vivo studies, compound 38 showed high D2R receptor occupancy in mice and effectively inhibited phencyclidine-induced hyperlocomotion.
    DOI:
    10.1021/acs.jmedchem.9b00508
  • 作为产物:
    描述:
    2-氟苯甲醛吡啶platinum(IV) oxide 、 aluminum (III) chloride 、 potassium tert-butylate氢气溶剂黄146 作用下, 以 甲醇二氯甲烷叔丁醇 为溶剂, 85.0 ℃ 、344.75 kPa 条件下, 反应 42.5h, 生成 8-氟-1,2,3,4-四氢异喹啉
    参考文献:
    名称:
    [EN] SMALL MOLECULE ACTIVATORS OF NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE (NAMPT) AND USES THEREOF
    [FR] ACTIVATEURS À PETITES MOLÉCULES DE NICOTINAMIDE PHOSPHORIBOSYLTRANSFÉRASE (NAMPT) ET LEURS UTILISATIONS
    摘要:
    本文提供了尼古丁酰胺磷酸核糖转移酶(NAMPT)的小分子激活剂,包括这些化合物的组合物,以及使用这些化合物和组合物的方法。
    公开号:
    WO2018132372A1
点击查看最新优质反应信息

文献信息

  • TRPV3 Modulators
    申请人:Clapham Bruce
    公开号:US20120245124A1
    公开(公告)日:2012-09-27
    Disclosed herein are modulators of TRPV3 of formula (I) wherein X 1 , X 2 , R 1 , R 2 , R x , and n are as defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also presented.
    本文披露了具有如下式(I)的TRPV3调节剂,其中X1、X2、R1、R2、Rx和n如规范中定义。还提供了包含这种化合物的组合物以及使用这种化合物和组合物治疗疾病和疾病的方法。
  • Synthesis of 8-Fluoro-3,4-dihydroisoquinoline and Its Transformation to 1,8-Disubstituted Tetrahydroisoquinolines
    作者:Csilla Hargitai、Tamás Nagy、Judit Halász、Gyula Simig、Balázs Volk
    DOI:10.3390/molecules23061280
    日期:——
    A simple procedure for the synthesis of 8-fluoro-3,4-dihydroisoquinoline is described below, based on a directed ortho-lithiation reaction. This key intermediate was then applied in various transformations. Fluorine⁻amine exchange afforded the corresponding 8-amino-3,4-dihydroisoquinolines, suitable starting compounds for the synthesis of 1-substituted 8-amino-tetrahydroisoquinolines. On the other
    基于定向邻位锂化反应,以下描述了用于合成8-氟-3,4-二氢异喹啉的简单方法。然后将该关键中间体应用于各种转化中。氟⁻胺交换得到相应的8-氨基-3,4-二氢异喹啉,是合成1-取代的8-氨基-四氢异喹啉的合适起始化合物。另一方面,8-氟-3,4-二氢异喹啉的还原和烷基化反应导致了新的1,2,3,4-四氢异喹啉衍生物,可以用作合成潜在的中枢神经系统候选药物的基础。
  • Affinity of 2-(tetrahydroisoquinolin-2-ylmethyl)- and 2-(isoindolin-2-ylmethyl)imidazolines for .alpha.-adrenoceptors. Differential affinity of imidazolines for the [3H]idazoxan-labeled .alpha.2-adrenoceptor vs the [3H]yohimbine-labeled site
    作者:Robin D. Clark、Jacob Berger、Pushkal Garg、Klaus K. Weinhardt、Michael Spedding、Andrew T. Kilpatrick、Christine M. Brown、Alison C. MacKinnon
    DOI:10.1021/jm00164a021
    日期:1990.2
    A series of 2-(tetrahydroisoquinolin-2-ylmethyl)- and 2-(isoindolin-2-ylmethyl)imidazolines were prepared and tested for alpha 1- and alpha 2-adrenoceptor affinity with radioligand binding. Several compounds, 5-fluoro-(5h), 5-chloro-(5j), 5,8-dimethoxy- (5r), and 5,8-dimethoxy- (5r),1-methyl- (5s) 2-(tetrahydroisoquinolin-2- ylmethyl)imidazoline, were found to be selective alpha 2-adrenoceptor ligands
    制备一系列2-(四氢异喹啉-2-基甲基)-和2-(异吲哚-2-基甲基)咪唑啉,并通过放射性配体结合测试α1-和α2-肾上腺素受体的亲和力。几种化合物5-氟-(5h),5-氯-(5j),5,8-二甲氧基-(5r)和5,8-二甲氧基-(5r),1-甲基-(5s)2-(基于[3H]育亨宾从大鼠大脑皮膜的置换,发现四氢异喹啉-2-基甲基)咪唑啉是选择性的α2-肾上腺素受体配体。一种化合物2-[((8-氯四氢异喹啉-2-基)甲基]咪唑啉(5m)与[3H]育亨宾相比,对[3H] idazoxan标记的α2-肾上腺素受体的亲和力显示出36倍的差异-标记的位点,可能是α2-肾上腺素受体亚型的证据。
  • [EN] SUBSTITUTED BENZAMIDE DERIVATIVES AND THEIR USE AS ANTICONVULSANTS<br/>[FR] DERIVES SUBSTITUES DU BENZAMIDE ET LEUR UTILISATION COMME ANTICONVULSIVANTS
    申请人:SMITHKLINE BEECHAM PLC
    公开号:WO1997048683A1
    公开(公告)日:1997-12-24
    (EN) The invention relates to substituted benzamido-heterocyclic compounds of general formula (I) having an alkoxy substituent at the C2 position of the benzamido group and various substituents at positions C4 and C5, being optionally substituted on the N atom of the heterocyclic system, and where the unsaturated ring of the heterocyclic system is a 5, 6, 7 or 8-membered ring. Also to the use of these compounds as anticonvulsants in certain medical conditions, and to processes for making them.(FR) L'invention concerne des composés benzamido-hétérocycliques substitués, de formule générale (I), comportant un substituant alcoxy en position C2 du groupe benzamido et divers substituants aux positions C4 et C5; éventuellement substitués sur l'atome N du système hétérocyclique; et dans lesquels le noyau insaturé du système hétérocyclique est un noyau à 5, 6, 7 ou 8 éléments. L'invention concerne également l'utilisation de ces composés comme anticonvulsivants dans certains troubles médicaux, ainsi que les procédés permettant de les fabriquer.
    本发明涉及一般式(I)的取代苯甲酰胺-杂环化合物,其在苯甲酰胺基团的C2位置具有烷氧基取代基,在C4和C5位置具有各种取代基,可以在杂环系统的N原子上选用取代基,且杂环系统的不饱和环为5、6、7或8元环。此外,本发明还涉及将这些化合物用作某些医疗条件下的抗惊厥药物,以及制备它们的过程。
  • [EN] COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING FGF ACTIVITY<br/>[FR] COMPOSÉS, COMPOSITIONS ET PROCÉDÉS DE MODULATION DE L'ACTIVITÉ FGF
    申请人:RECOVERY THERAPEUTICS INC
    公开号:WO2022174083A1
    公开(公告)日:2022-08-18
    The invention features compounds which modulate FGF activity, e.g., by enhancing the binding between FGF-2 and its receptors, e.g., FGF-R1. Also featured is a pharmaceutical composition containing one or more of the compounds, a method of treating an injury or a disease e.g., stroke, congenital hypogonadotropic hypogonadism, and viral infection, and a method of increasing spermatogenesis using the pharmaceutical composition.
    本发明涉及调节FGF活性的化合物,例如,通过增强FGF-2与其受体(例如FGF-R1)之间的结合。此外,本发明还涉及一种含有一种或多种该化合物的制药组合物,一种治疗损伤或疾病(例如中风、先天性低促性腺激素性性腺功能减退症和病毒感染)的方法,以及一种使用该制药组合物增加精子生成的方法。
查看更多